Shares of Eli Lilly surged as an FDA advisory committee endorsed donanemab, an Alzheimer's treatment shown to significantly impact early-stage patients. The drug's benefits outstripped risks, setting the stage for a final FDA decision.
U.S. stock futures point to a weak start on Tuesday, signaling a pause after Monday’s record run. Global cues are negative and commodity prices weakened as well.